18 June 2018
Visiongain’ has launched a new pharma report Global Biosimilars and Follow-On Biologics Market : Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones
A biosimilar is a biological drug that is ‘highly’ similar to an already approved branded biologic. Patents on many leading biologic products are set to expire in the coming years, opening them up to biosimilar competition and offering hope to patients and nations alike. The market is set to experience rapid growth between 2016 and 2028, with many pharmaceutical companies developing biosimilars to take advantage of that market’s vast potential and patients’ needs. Biosimilars are already well-established in emerging markets, however developed markets have traditionally lagged behind.
The lead analyst of the report commented “The US is not the only country that will drive growth in the global biosimilars market. Other developed markets, such as those in Europe, present an opportunity for growth. Many of these nations face huge deficits in their national healthcare budgets and are in need of the huge savings that biosimilars can provide. This is especially true given the rising prevalence of chronic diseases which are placing a huge strain on national healthcare budgets.
Emerging markets have traditionally posed the best opportunity for growth for biosimilars, and they will continue to be a source of growth throughout the forecast period. These nations have limited budgets, combined with large ageing populations, which presents a need for biosimilar therapies. Biosimilars offer these nations a way to widen access to healthcare at a reasonable cost.”
Leading companies featured in the report include Sandoz, Teva, Hospira, Celltrion, Amgen, Dr. Reddy’s Laboratories, 3SBio, Wockhardt , Ranbaxy, LG Life Sciences, Biocad, Boehringer Ingelheim, PROBIOMED
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.